Conference LibraryGated
Claim · Lymphodepletion-free in vivo CAR-T is now empirically demonstrated
Two distinct in vivo CAR-T modalities have demonstrated CAR generation in patient or animal models WITHOUT prior lymphodepletion · Bajbouj/Puré (Cancer Immunol Res 2026 · PMID 41686204) showed FAP-CAR tLNP delivery achieving >45% splenic / >69% circulating / >35% tumor-infiltrat…
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_synthesis_round_8_2026-05-16
- evidence_grade
- A
- category
- in_vivo_lymphodepletion_free_claim
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "Synthesis claim · preclinical FAP-CAR + phase 1 ESO-T01 · lymphodepletion-free pathway is feasibility-demonstrated · NOT yet validated late-stage outcome · not intended to guide individual patient
- claim_statement
- Two distinct in vivo CAR-T modalities have demonstrated CAR generation in patient or animal models WITHOUT prior lymphodepletion · Bajbouj/Puré (Cancer Immunol Res 2026 · PMID 41686204) showed FAP-CAR tLNP delivery achieving >45% splenic / >69% circulating / >35% tumor-infiltrati
- claim_evidence_grade
- A
- supporting_papers
- m622-b5-paper-fap-car-tlnp-2026-001,m622-b5-paper-naturemed-esot01-001,m622-b5-paper-lancet-esot01-001,m622-b5-paper-bmt-bridging-bcma-2026-001,m622-b5-paper-jco-caremm-2026-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.